Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
1 finding from 1 review
Serious adverse events · people with active UC
1 finding from 1 review
Serious adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
Serious adverse events · people with active UC
Antibiotics showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
It is very uncertain whether antibiotics plus probiotics changes serious adverse events compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with SASP (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Once daily dosing showed no clear difference in serious adverse events compared with conventional dosing (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with comparator 5‐ASA (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active mild to moderate ulcerative colitis
Oral 5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · people with active UC
It is very uncertain whether probiotics changes serious adverse events compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Serious adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
Antibiotic showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in serious adverse events (low certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).
1 finding from 1 review